Replies to post #233153 on Biotech Values

[DewDiligence]

RVNC—They'll be back in the market prior to any meaningful revenues from their Daxi line.

You would probably say that even if RVNC had $3B in cash.

I'm highly suspect that they'll never reap anything meaningful from the filler line.

Ha! If you actually mean that, we’re in full agreement.